Sartorius and BD Diagnostics Collaborate On Microbiological Diagnostics
Sartorius and BD Diagnostics plan to collaborate on ready-to-use, prefilled media products for microbiological applications.
Sartorius Stedim Biotech and BD Diagnostics, a segment of BD (Becton, Dickinson and Company) a medical technology company, reported a collaboration to develop, manufacture, and market various ready-to-use, prefilled media products for microbiological applications in pharmaceutical, biotech, and research laboratories.
As part of this collaboration, BD will fill special Sartorius single-use products with BD culture media and supply these to Sartorius as prepackaged products. Both companies are looking to further extend their existing business relationship by pursuing other solutions in the field of microbiological diagnostics.
Source: Sartorius Stedim Biotech
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
